Nanobiotix (NASDAQ:NBTX) Shares Gap Up – Should You Buy?

Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) gapped up before the market opened on Friday . The stock had previously closed at $40.18, but opened at $42.50. Nanobiotix shares last traded at $41.5610, with a volume of 18,311 shares.

Wall Street Analysts Forecast Growth

NBTX has been the subject of several recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. Guggenheim raised their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the stock a “buy” rating in a report on Thursday, April 2nd. UBS Group raised their price objective on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Finally, TD Cowen reissued a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $26.67.

Nanobiotix Price Performance

The stock’s 50-day moving average price is $35.69 and its 200-day moving average price is $27.55.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The firm had revenue of $3.42 million for the quarter. On average, research analysts anticipate that Nanobiotix S.A. – Sponsored ADR will post 0.19 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of NBTX. Royal Bank of Canada boosted its stake in Nanobiotix by 2,000.0% during the 4th quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. Optiver Holding B.V. acquired a new position in Nanobiotix during the 3rd quarter valued at about $101,000. Marshall Wace LLP acquired a new position in Nanobiotix during the 4th quarter valued at about $220,000. Finally, Millennium Management LLC acquired a new position in Nanobiotix during the 4th quarter valued at about $390,000. 38.81% of the stock is currently owned by institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.